Company news

Sihuan Pharmaceutical Holdings Group Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

November 2, 2026

Voluntary announcement- phase III clinical study data of xuanzhu biopharm's Anaprazole Sodium for reflux esophagitis presented at UEG Week 2026

October 21, 2026

Voluntary announcement - polycaprolactone microsphere facial filler for Injection and hyaluronic acid sodium composite solution for Injection independently developed by meiyan space, a subsidiary of Sihuan Pharmaceutical, approved for market launch in hong kong

October 20, 2026

Voluntary announcement-Sihuan Pharmaceutical completed a strategic investment in canton biologics to enhance the layout of the entire industrial chain of regenerative medical aesthetics

October 8, 2026

Voluntary announcement - new specifications of skin booster (brand name: dongyan) of Sihuan Pharmaceutical approved for launch by nmpa

October 5, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 2, 2026

Notification Letter and Request Form to Non-registered Holder

September 16, 2026

Notification Letter and Change Request Form to Registered Shareholder

September 16, 2026

Interim Report 2026

September 16, 2026

Voluntary announcement - insulin aspart 30 injection developed by Sihuan Pharmaceutical achieved equivalent clinical results in efficacy and safety study as originator drug

July 30, 2021

Voluntary announcement-entering into strategic cooperation agreement between jilin huisheng biopharmaceutical and porton pharma

April 28, 2021

Voluntary announcement - share repurchase

April 9, 2021

Voluntary announcement-Sihuan Pharmaceutical obtained drug registration approval in relation to ambroxol hydrochloride injection

April 1, 2021

Voluntary announcement proposed share repurchase under the general mandate

March 28, 2021

Voluntary announcement Sihuan Pharmaceutical obtained drug registration approval in relation to rivaroxaban tablets

March 25, 2021

Sihuan Pharmaceutical Holdings Group: Voluntary announcement the group's liraglutide has completed phase i clinical study for indication of weight loss

February 25, 2021

Voluntary announcement official release of the result of large-scale clinical trials after the launch of cinepazide maleate injection the drug takes stroke treatment into a new era with its verified efficacy

August 21, 2020

Voluntary announcement - capital injection by new investors into beijing ruiye drugs manufacture co., ltd. (an associate of Sihuan Pharmaceutical) to accelerate capacity expansion

August 19, 2020

Notice of board meeting

August 13, 2020

Voluntary announcement - acquisition of all interests and intellectual property rights of plazomicin, a new generation of aminoglycoside antibiotics in the greater china region

February 20, 2020

Voluntary announcement - production approval granted for rivastigmine hydrogen tartrate capsule, the first drug passing consistency evaluation and levetiracetam tablet and the first registration approval granted for midazolam oromucosal solution

February 18, 2020

VOLUNTARY ANNOUNCEMENT - Commencement of Phase III Clinical Trial in the PRC for Self-Developed Innovative Patented Drug "Anaprazole Sodium" and Inclusion of "Huineng" into the National Reimbursement Drug List

February 13, 2020

Voluntary announcement - Sihuan Pharmaceutical and hetero labs limited reached a framework cooperation agreement in pharmaceutical manufacturing area

February 11, 2020

Sihuan Pharmaceutical has been Granted the Drug Registration Approval for Another Solid-Liquid Double Chamber Bag, and is the First Company in China that Obtained Drug Registration Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Cefuroxime Sodium/Sodium Chloride Injection"

June 19, 2019

Decks

The 5 newest of 8 decks. Every deck is listed under its year.